What Is Erasca, Inc. (ERAS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Erasca, Inc.'s intrinsic value is estimated at $7.95, suggesting the stock is overvalued at its current price of $21.26. With 10 out of 10 models flagging downside (-62.6% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: First Chicago targets $16.88 (-20.6%), versus ML-RIV at $0.94 (-95.6%). This +75.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ERAS?
10 of 13 models are currently active for ERAS. All 10 active models suggest the stock trades above fair value. The Bayesian DCF estimates ERAS's intrinsic value at $4.10, implying -80.7% downside from the current price. See which stocks rank higher →
How Does ERAS Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, ERAS ranks #308 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a biopharma enterprise, Erasca, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating ERAS should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ERAS a Value Trap?
CirclFi's Value Trap algorithm assigns ERAS a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Erasca, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Erasca, Inc.'s fundamental quality profile registers 4.2/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +75.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ERAS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ERAS's 10 active models, average confidence is 38%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad